On July 11, the Colorado Prescription Drug Affordability Board (PDAB or Board) held its second upper payment limit (UPL) rulemaking hearing for the autoimmune drug Enbrel, moving closer to becoming the first state PDAB to try to implement this ill-conceived mechanism to control drug costs.
In advance of the July 11 hearing, Colorado BioScience Association (CBSA) and Biotechnology Innovation Organization (BIO) submitted joint written testimony discussing our serious, continuing concerns about UPLs as a tool to accomplish the PDAB’s goals and, more specifically, about the lack of a concrete methodology for determining UPLs in a clear, consistent manner. We strongly urged the PDAB to pause before setting any UPLs and make sure it has taken all appropriate steps before moving forward with this first-of-its-kind UPL rulemaking.
Before the first UPL rulemaking hearing on May 23, CBSA and BIO…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
